Phase 2 N=62 Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)
Ovarian Cancer
Primary: PFS — 29.8 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=28 Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
Primary Peritoneal Carcinoma · Ovarian Carcinoma · Fallopian Tube Carcinoma
Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants
Phase 2 N=18 Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer
Ovarian Neoplasms Malignant (Excl Germ Cell) · Peritoneal Carcinoma · Fallopian Tube Cancer
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
Phase 2 N=32 Neoadjuvant Therapy for Ovarian Cancer
Epithelial Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer
Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events
Phase 2 N=95 Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Primary: Objective Response Rate (ORR) — 1; 11; 7; 8 Participants
Phase 1 N=7 Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer
Ovarian Cancer
Primary: Number of Patients With Dose-limiting Toxicities (DLTs) — 0; 0 Participants
Phase 2 N=218 Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer
Neoplasms · Cancer of the Ovary
Primary: Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by an Independent Review…
Phase 2 N=59 Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Consolidation Progression-Free Survival — 13.3; 18.9 months
Phase 2 N=132 TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary
Ovarian Cancer
Primary: Twelve-month Progression-free Survival (PFS) Rate in Participants — 65.7 percentage of participants
Phase 3 N=1,301 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…
Phase 1 N=15 Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2
Phase 2 N=31 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Fallopian Tube Carcinoma · Malignant Ovarian Mixed Epithelial Tumor · Ovarian Brenner Tumor
Primary: Progression-free Survival at 6 Months — 6.5 percentage of participants
Phase 2 N=29 Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Ovarian Cancer
Primary: Progression Free Survival (PFS) of Combination Platinum Based Therapy With Anti-Programmed Death (PD)-1 Therapy Followed by Maintenance Anti-PD-1 Therapy in Patients…
Phase 2 N=58 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Overall Survival — 32 months
Phase 2 N=64 Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer · Stage IV Ovarian Epithelial Cancer
Primary: Progression-free Survival at 6 Months — 40.3 percentage of participants
Phase 3 N=361 AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Ovarian Cancer
Primary: Percentage of Participants With Disease Progression or Death (Data Cutoff 14 November 2011) — 92.3; 78.8 percentage of participants
Phase 2 N=56 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
Brenner Tumor · Fallopian Tube Cancer · Ovarian Clear Cell Cystadenocarcinoma
Primary: Pathologic Complete Response Rates — 8 participants
Phase 2 N=45 Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Recurrent Ovarian Epithelial Cancer · Recurrent Primary Peritoneal Cavity Cancer · Stage IIIA Ovarian Epithelial Cancer
Primary: Proportion of Confirmed Tumor Responses Defined to be Either a Complete Response (CR) or Partial Response (PR) — 2.5; 0; 15; 40 Percentage of Participants
Phase 2 N=122 European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma
Primary: Progression-free Survival — 8.85; 8.32 months
Phase 3 N=4,312 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Primary Peritoneal Carcinoma · Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Overall Survival — 0.35; 0.34; 0.39; 0.34 Proportion of participants
Phase 2 N=26 Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
Ovarian Cancer
Primary: Patients' Overall 90-Day Clinical Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) — 8; 18 Participants
Phase 1 N=13 Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants
Phase 2 N=74 Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
Recurrent Fallopian Tube Cancer · Recurrent Ovarian Epithelial Cancer · Recurrent Primary Peritoneal Cavity Cancer
Primary: Response Benefit (Complete Response or Partial Response or Stable Disease) Based on the RECIST/Rustin Criteria — 9; 0 participants
Phase 2 N=211 AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
Ovarian Neoplasms · Ovarian Cancer
Primary: Objective Response Rate as Evaluated by Response Evaluation Criteria In Solid Tumors ( RECIST) — 47; 45 Participants
Phase 3 N=1,560 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Mucinous Adenocarcinoma
Primary: Median Progression-free Survival — 24.9; 27.3; 26.0 months — p=0.341
Phase 1 N=9 Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer
Primary: Tolerated Dose — 80 mg/m^2
Phase 2 N=44 RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Four Cycle Progression-free Survival Rate — 8 Participants
Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Phase 2 N=40 Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer
Ovarian Neoplasms
Primary: Objective Response (Complete Partial, Stable and Progression) — 1; 8; 10; 20 Participants
N/A N=11 Evaluation of Response to the Neoadjuvant Chemotherapy for Advanced Ovarian Cancer by Multimodal Functional Imaging
Ovarian Cancer
Primary: Inter-rater Reliability of Positron Emission Tomography (PET) Maximum Standardized Uptake Value (SUVmax) - Individual Intra-class Correlation Coefficients by Location…